Daytrana Approved - Shire plc - Treatment for Attention Deficit Hyperactivity Disorder
Daytrana is a once daily transdermal patch formulation of methylphenidate indicated for the treatment of attention deficit hyperactivity disorder (ADHD).Posted: April 2006
Related Articles:
- FDA Approves Daytrana (methylphenidate transdermal system) CII for the Treatment of ADHD in Adolescents - July 7, 2010
- FDA Declares Daytrana NDA Resubmission to Be Complete Class I Response - March 10, 2006
- FDA Issues Approvable Letter for Daytrana Methylphenidate Transdermal System - December 23, 2005
- Noven to Commence Manufacture of Daytrana Methylphenidate Transdermal System - December 13, 2005
- Noven Announces Results of Daytrana Advisory Committee Meeting - December 2, 2005
- Developmental Methylphenidate Patch Scheduled for FDA Advisory Committee Review - October 27, 2005
- Shire and Noven Resubmitted NDA for MTS, a Candidate Treatment for Pediatric ADHD Patients - July 26, 2005
